People
Halozyme Therapeutics will halt development of a metastatic pancreatic cancer drug after it failed to demonstrate an improvement in overall survival in a Phase III trial.
Late Friday, President Donald Trump put forth Hahn’s name to take over the top spot of the nation’s regulatory agency.
Liquidia Technologies, Inc. announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors as a Class II director with a term expiring at the 2020 annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee.
Peli BioThermal, the global name in temperature controlled packaging, officially announced the appointment of Ray Crane as vice president of worldwide operations.
Companies strengthen their leadership teams and boards of directors with this week’s slate of Movers & Shakers.
Albany College of Pharmacy and Health Sciences announces that Kamal A. Rashid, Ph.D. has been named founding director of the College’s new Center for Biopharmaceutical Education and Training, a $37.3 million training center dedicated to workforce development in the rapidly growing biopharmaceutical industry.
Caldwell has more than 30 years’ international executive management experience in the manufacture of industrial gases, specialty gases, and chemicals, serving the electronics, pharmaceutical, chemical, research, and high-technology industries.
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
Chief Financial Officer David Meline said the decision was made in order to provide the financial support to areas that will provide long-term growth for the company.
Reynolds claimed that his company’s product, called NeuroRelease, could essentially end paralysis.
PRESS RELEASES